NLS Pharmaceutics将执行1比10的反向股份分割

2025-10-29 18:22

Swiss drugmaker NLS Pharmaceutics (NASDAQ:NLSP) plans to implement a reverse share split of its issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10.
The shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, 2025, under the new trading symbol "NCEL", and new name, NewcelX Ltd., following the anticipated closing of the merger with Kadimastem (OTC:KMSTF).
NLSP -4.7% premarket.

More on NLS Pharmaceutics